Distinct antischistosomal profiles of antimalarials and TRP agonists
- 1University of Wisconsin - Madison
Abstract
Schistosomiasis control relies on praziquantel mass drug administration, but reports of field treatment failure and laboratory-selected resistance highlight the need for alternatives. Praziquantel activates a schistosome transient receptor potential (TRP) channel, TRPMPZQ. Alternative leads or chemotherapies include meclonazepam, which activates a distinct schistosome TRP channel, and the antimalarials artemether and mefloquine, whose flatworm targets are unknown. To compare molecular responses and assess cross-resistance, we conducted comparative RNA-seq and efficacy studies in infected mice. We profiled adult Schistosoma mansoni recovered 48 hours after artemether or mefloquine treatment and compared responses with existing datasets for TRP agonists praziquantel and meclonazepam. Transcriptional profiles clustered by drug class but showed largely distinct changes, with only 33 upregulated and 63 downregulated transcripts shared across treatments. Plexin domain-containing genes were strongly induced by both TRP agonists and, to a lesser extent, by antimalarials. Artemether downregulated gene families expressed in intestinal cells (saposins, cathepsins, and Bax inhibitor-like proteins), consistent with potential heme-dependent activity in the schistosome gut. Genes involved in glutamine metabolism, iron homeostasis and responses to oxidative damage were upregulated across multiple treatments. We evaluated all four treatments in mice infected with praziquantel-susceptible or resistant parasites. Praziquantel (200 mg/kg) reduced resistant male worm burdens by only 39.3%, versus 99.0% in susceptible parasites. Meclonazepam (83.0% versus 91.6% in susceptible parasites), mefloquine (99.1% versus 98.8%), and artemether (98.2% versus 99.4%) retained activity. The distinct transcriptional responses and retained activity against praziquantel-resistant parasites support further investigation of these compound classes as praziquantel alternatives or potential combination partners.
Related
- Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
- The Psychology of GLP-1 Receptor Agonists: Evidence for Distinct Effects on Reward, Interoception and Cognition
- Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database
- Distinct temporal neuropsychiatric outcomes associated with GLP-1 receptor agonists versus SGLT2 inhibitors after acute kidney disease in type 2 diabetes
- Distinct Liver Enzyme Profiles in Non-Diabetic Obesity: Associations with Obesity Severity and Metabolic Dysfunction
BibTeX
@misc{wheeler2026distinct,
title = {{Distinct antischistosomal profiles of antimalarials and TRP agonists}},
author = {N. J. Wheeler and M. Zamanian and J. D. Chan},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.761559},
url = {https://www.biorxiv.org/content/10.64898/2026.10.29.761559v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Distinct antischistosomal profiles of antimalarials and TRP agonists
AU - N. J. Wheeler
AU - M. Zamanian
AU - J. D. Chan
PY - 2026
DA - 2026/10/29
PB - bioRxiv
DO - 10.64898/2026.10.29.761559
UR - https://www.biorxiv.org/content/10.64898/2026.10.29.761559v1
AB - Schistosomiasis control relies on praziquantel mass drug administration, but reports of field treatment failure and laboratory-selected resistance highlight the need for alternatives. Praziquantel activates a schistosome transient receptor potential (TRP) channel, TRPMPZQ. Alternative leads or chemotherapies include meclonazepam, which activates a distinct schistosome TRP channel, and the antimalarials artemether and mefloquine, whose flatworm targets are unknown. To compare molecular responses and assess cross-resistance, we conducted comparative RNA-seq and efficacy studies in infected mice. We profiled adult Schistosoma mansoni recovered 48 hours after artemether or mefloquine treatment and compared responses with existing datasets for TRP agonists praziquantel and meclonazepam. Transcriptional profiles clustered by drug class but showed largely distinct changes, with only 33 upregulated and 63 downregulated transcripts shared across treatments. Plexin domain-containing genes were strongly induced by both TRP agonists and, to a lesser extent, by antimalarials. Artemether downregulated gene families expressed in intestinal cells (saposins, cathepsins, and Bax inhibitor-like proteins), consistent with potential heme-dependent activity in the schistosome gut. Genes involved in glutamine metabolism, iron homeostasis and responses to oxidative damage were upregulated across multiple treatments. We evaluated all four treatments in mice infected with praziquantel-susceptible or resistant parasites. Praziquantel (200 mg/kg) reduced resistant male worm burdens by only 39.3%, versus 99.0% in susceptible parasites. Meclonazepam (83.0% versus 91.6% in susceptible parasites), mefloquine (99.1% versus 98.8%), and artemether (98.2% versus 99.4%) retained activity. The distinct transcriptional responses and retained activity against praziquantel-resistant parasites support further investigation of these compound classes as praziquantel alternatives or potential combination partners.
ER -